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a  b  s  t  r  a  c  t
Colorectal cancer is linked to several signaling pathways such as Wnt pathway. Our objec-
tive is to detect and verify the integrity of protein members of Wnt signaling pathway in
colorectal carcinoma and non-neoplastic colorectal tissue. Sixty-four patients with colorec-
tal  carcinoma provided samples of colorectal neoplasia and non-neoplastic tissues, which
were prepared in tissue microarray blocks and subjected to immunohistochemical analysis.
The primary antibodies used were Wnt-1, Wnt-2, Wnt-5a Frizzled-1, Frizzled-5 and axin.
Immunoexpression of Wnt-2 protein was signiﬁcantly lower in colorectal tumor tissue and
axin  protein immunoexpression was signiﬁcantly higher in tumor tissue. There was no sig-
niﬁcant difference in the expression of Wnt-1, Wnt-5a, Frizzled-1 and Frizzled-5 proteins
in  both tissues. The higher expression of Wnt-2 protein in non-neoplastic colorectal tis-
sue suggests the participation during the hyperproliferative stage of colorectal mucosa. The
increased axin protein immunoexpression in colorectal tumor suggests a decrease in the
formation of the -catenin destructor complex.
©  2015 Sociedade Brasileira de Coloproctologia. Published by Elsevier Editora Ltda. All
rights reserved.
Estudo  imunoistoquímico  da  via  de  sinalizac¸ão  canônica  e  não  canônica
da  proteína  Wnt  em  carcinoma  colorretal  e  em  mucosa  não  neoplásicaPalavras-chave:
Neoplasias colorretais
r  e  s  u  m  o
O câncer colorretal está ligado a várias vias de sinalizac¸ão, como a via Wnt. Nosso objetivo
é  detectar e veriﬁcar a integridade das proteínas da via de sinalizac¸ão Wnt no carcinoma
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Proteínas Wnt
Receptores frizzled
Complexo de sinalizac¸ão da
axina
Imunoistoquímica
colorretal e no tecido colorretal não neoplásico. Sessenta e quatro pacientes com carci-
noma colorretal forneceram amostras de neoplasia e tecidos não neoplásicos, que foram
colocadas em blocos de tissue microarray e submetidas à análise imuno-histoquímica. Os
anticorpos primários utilizados foram Wnt-1, Wnt-2, Wnt-5a Frizzled-1, Frizzled-5 e axina.
A  imunoexpressão da proteína Wnt-2 foi signiﬁcativamente menor no tecido tumoral e a
imunoexpressão da proteína axina foi signiﬁcativamente superior no tecido do tumor. Não
houve diferenc¸a signiﬁcativa na expressão de Wnt-1, Wnt-5a, frizzled-1 e nas proteínas Friz-
zled  1 e 5 em ambos os tecidos. A maior expressão de Wnt-2 da proteína no tecido colorretal
não neoplásico sugere a participac¸ão desta proteína durante o estágio de hiperproliferac¸ão
da  mucosa colorretal. O aumento da imunoexpressão da proteína axina no tumor colorretal
sugere uma diminuic¸ão na formac¸ão do complexo de destruic¸ão da proteína - catenina.
©  2015 Sociedade Brasileira de Coloproctologia. Publicado por Elsevier Editora Ltda.




































orldwide, colorectal cancer (CRC) is the third most common
alignancy in men  and the second most common in women.1
In the lower portion of the crypts of Lieberkühn, there
re stem cells that are responsible for the proliferation, dif-
erentiation and self-renewing of the colon epithelium.2 The
aintenance of the stem cell compartment and the transition
rom proliferation to differentiation are regulated by Wnt  cell
ignaling receptors (Wingless and wnt-related protein).3
The Wnt  pathway acts during embryogenesis in verte-
rates and invertebrates and in the regulation of cellular
roliferation, differentiation and apoptosis.4
Frizzled, LRP (low-density lipoprotein receptor-related pro-
ein) 5 and LRP 6 are participating receptors in the canonical
nt  signaling pathway, inducing stabilization of the -catenin
rotein in the cytoplasm. This regulation of stability is
ediated by the APC (adenomatous polyposis coli) tumor sup-
ressor gene through a complex of proteins that also includes,
xin, GSK3 (glycogen synthase kinase 3) and CK1 (casein
inase 1), which form the so-called destructor complex of -
atenin. Axin/-catenin interaction is an important control
oint for the Wnt  pathway that plays a role in tumor genesis.5
he increase in the pool of -catenin in the cytoplasm by Wnt
timulation occurs due to blocking of the destructor complex
y the Disheveled (Dsh) protein, mediating the transcription
f Wnt  target genes in the nucleus.6 Deletions or mutations
n the axin gene have been observed in various tumor types,
ncluding CRC and hepatocellular carcinoma.7
The non-canonical pathway is a generic term for all Wnt
ignaling pathways that promote transcription that is not
ediated by -catenin8 and is activated by Frizzled receptors
ndependently of the activation of LRP 5 and LRP 6.
The canonical pathway has received considerable atten-
ion over the years due to its essential role in the homeostasis
f the colon epithelium and in the genesis of CRC. However,
he mechanisms of action of the non-canonical Wnt  signaling
athway in CRC are not yet completely understood.9In mammals, 19 types of Wnt  proteins have been
escribed.9 Some Wnt  proteins such as Wnt-3 and Wnt-1 can
ctivate both the canonical pathway and the non-canonical
athway, while others, such as Wnt-5a protein, appear to bespeciﬁc to the non-canonical pathway.8 Frizzled receptors can
receive signals from one or more  proteins of the Wnt  pathway,
such as the Frizzled-5 receptor, which receives signals from
both the canonical pathway (Wnt-2) and the non-canonical
pathway (Wnt-5a).10
In CRC, Wnt-1 and Wnt-2 proteins are considered stim-
ulators of carcinogenesis,11,12 whereas the Wnt-5a protein
appears to have tumor suppressor characteristics.10 However,
the real role of Frizzled receptors in colorectal carcinogenesis
remains obscure.13
Identiﬁcation of regulatory proteins involved in the Wnt
pathway offers opportunities to develop new therapies
directed at CRC14,15 using monoclonal antibodies against ther-
apeutic targets such as the Wnt-1 and Wnt-2 proteins and
for the axin protein and Frizzled receptors.16 De Almeida
et al.17 showed that a soluble biological receptor was capable
of blocking the autocrine Wnt  signal in vitro, and experiments
in mice showed no signs of toxicity after several weeks. He
et al.18 developed a monoclonal antibody capable of blocking
the Wnt-1 protein and observed increased apoptosis in CRC
cell lines. Although still in phase I, these studies have already
demonstrated that the use of the Wnt  signaling pathway as a
possible therapeutic target is promising.
The aim of this study was to investigate the canonical and
non-canonical pathways of Wnt  signaling in colorectal carci-
noma and adjacent non-neoplastic colorectal mucosa through
the immunoexpression of Wnt-1, Wnt-2, Wnt-5a, Frizzled-1,
and Frizzled-5 and axin proteins.
Method
Samples
This study was approved by the Research Ethics Committees of
the participating institutions. The study was conducted using
samples from 64 patients with CRC who underwent cura-
tive or palliative surgery. Thirty-four (53%) patients were men
and 30 (47%) were women. The median age was 69.2 (range,
41–94 years). Colorectal tissue samples were obtained from 64
patients who underwent surgery for CRC and were divided into
two groups: group A – tissue samples from CRC; and group
j). 2 0158  j coloproctol (rio 
B – tissue samples obtained from non-neoplastic colorectal
mucosa located 10 cm cranial to the tumor.
Histopathological  analysis
Tissue samples from CRC and non-neoplastic colorectal tis-
sues were ﬁxed in 10% formalin and embedded in parafﬁn
blocks for histological analysis. Conventional histological sec-
tions were prepared from each block at 3-m thick. All of the
slides were stained with hematoxylin–eosin (HE) and reviewed
by a pathologist for conﬁrmation of the diagnosis. To charac-
terize the histology, the histological grade of the malignancy
according to the International Classiﬁcation of Diseases for
Oncology (ICD-O) was used.
In the HE-stained slides, the surgical margins and best-
preserved areas most representative of the tumor were
marked to obtain the cylinder used in TMA  (tissue micro-
array). Areas of necrosis, hemorrhage and areas with low
cellularity were excluded. Next, the blocks were separated to
verify the quality and quantity of the tissue to be used and
to mark the areas for biopsy. The TMA  blocks were prepared
using a Beecher device (Beecher Instruments, Silver Spring,
MD, USA).
Immunohistochemistry
For immunohistochemical studies, the streptavidin-biotin
technique (LSAB-DakoCytomation, CA, USA) was used. The
polyclonal antibodies used were as follows: Wnt-1 (G-19) (goat)
(R&D Systems, Minneapolis, MN, USA), Wnt-2 (H-20) (goat)
(R&D Systems, Minneapolis, MN, USA), Wnt-5a (goat) (R&D
Systems, Minneapolis, MN, USA), Frizzled-1 (F-13) (goat) (R&D
Systems, Minneapolis, MN, USA), Frizzled-5 (L-12) (goat) (R&D
Systems, Minneapolis, MN, USA) and axin (H-98) (rabbit) (1:100
Santa Cruz Biotechnology Inc., CA, USA). All of the antibodies
were used at a 1:100 dilution.
For immunohistochemical studies, 4-m thick histologi-
cal sections were prepared according to previously described
techniques.19 Incubation with the antibodies was performed
in a moist incubation chamber at 4 ◦C for at least 16–18 h
(overnight). After three washes in PBS buffer pH 7.2–7.6, fur-
ther incubation was performed with biotinylated secondary
antibody (LSAB-DakoCytomation, CA, USA) in a humidiﬁed
chamber at room temperature for 30 min. Subsequently, the
same process was performed using a streptavidin-biotin-
peroxidase kit (LSAB-DakoCytomation, CA, USA). Washes
were then made with PBS buffer pH 7.2–7.6, and the color
was developed with liquid DAB (DakoCytomation, CA, USA) at
room temperature for 5 min. After washing in running water
for 3 min, counter-staining was performed using Harris hema-
toxylin for 1 min. The sections were dehydrated in 3 absolute
ethanol baths and 3 xylene baths and then mounted with
cover slips using Entellan resin (Sigma Chemical Co., Saint
Louis, MO, USA) for analysis in an optical microscope.
The immunoreactivity of the Wnt-1, Wnt-2, Wnt-5a,
Frizzled-1, Frizzled-5 proteins and axin was analyzed based
on the proportion of the number of positive cells (per-
centage of positivity) and the intensity of immunostaining
according to a standardized scale. The percentage of positive
cells or positivity was classiﬁed as follows: zero = less than 1 5;3  5(3):156–161
5% immunostained epithelial cells of the lesion; 1 = 5–25%;
2 = 26–50%; 3 = 51–75%; and 4 = more  than 76% immunostained
epithelial cells in the lesion. The intensity of immunoex-
pression was evaluated as follows: 0 = negative; 1+ = weak;
2+ = moderate; and 3+ = strong. The ﬁnal score was calculated
by multiplying the score of the percentage of positivity by the
score for the reaction intensity. The ﬁnal score was classiﬁed
as reduced expression (score value between 0 and 8) or strong
expression (score value between 9 and 12).20
All of the slides were analyzed by two independent exam-
iners considering only the degree of immunostaining and
without access to or knowledge of the anatomopathological
data. In cases of discrepancy in the evaluation, the slides were
re-evaluated, and a consensus evaluation was obtained.
Clinical  and  anatomopathological  data
The following clinical and anatomopathological data were
collected from the medical records of the patients: clin-
ical characteristics (age, gender, ethnicity), macroscopic
tumor characteristics (location, appearance, size), microscopic
characteristics (lymph node invasion, degree of cellular dif-
ferentiation, and venous, lymphatic and neural inﬁltration),
TNM21 classiﬁcation, presence of synchronous metastases,
and tissue immunoexpression of the antibodies used (percent-
age of positivity and intensity of immunoexpression).
Statistical  study
Quantitative results were reported as the median and
standard deviation. Qualitative data were described according
to the frequency of distribution. Associations between a pro-
tein’s positivity and the clinicopathological characteristics of
interest were evaluated using Fisher’s exact test. The level of
signiﬁcance adopted was 5% (p ≤ 0.05). Statistical analysis was
performed using SPSS software version 15.0 (The Predictive
Analytics Company, Chicago, IL, USA).
Results
Fifty-nine patients (92.2%) underwent curative surgery, and
5 patients (7.8%) underwent palliative surgery. The CRC was
located in the colon in 40 patients (62.5%) and in the rectum
in 24 patients (37.5%). Neoadjuvant therapy was administered
in 10 patients (15.6%), all of whom had rectal carcinoma.
The average size of a colorectal neoplasm was 5.2 (range,
0.5–12 cm). The size of the lesion in its largest diameter was
>5 cm in 43 patients (67.1%) and ≤5 cm in 21 patients (32.8%).
Lymph node metastasis was detected in 31 cases (48.4%), while
33 patients (51.6%) had lymph nodes free of any compromis-
ing neoplasm. Venous vascular invasion was observed in 21
patients (32.8%), lymphatic vascular invasion in 24 patients
(37.5%) and neural invasion in 12 patients (18.7%). In rela-
tion to the degree of cellular differentiation, 11 cases (17.2%)
were classiﬁed as well-differentiated carcinomas, 51 cases
(79.7%) as moderately differentiated and 2 cases (3.1%) as
poorly differentiated. The CRC had inﬁltrated superﬁcially
(T1 + T2) into the intestinal wall in 18 cases (28.1%) and had
inﬁltrated deeply (T3 + T4) in 46 cases (71.9%). Simultaneous
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Table 1 – Frequency of immunoreactivity scores of non-neoplastic colorectal tissues and colorectal carcinoma.
Protein expression NNCRT CRC p value
Strong Weak Strong Weak
Wnt-1 3/53 (5.6%) 50/53 (94.4%) 2/58 (3.4%) 56/58 (96.6%) 1.00
Wnt-2 19/60 (33.3%) 41/60 (66.7%) 10/62 (16.1%) 52/62 (83.9%) 0.05
Wnt-5a 0 49/49 (100%) 0 58/58 (100%) 0.28
Frizzled-1 4/52 (7.7%) 48/52 (92.3%) 3/42 (7.2%) 39/42 (92.8%) 0.70
Frizzled-5 0 50/50 (100%) 0 61/61 (100%) 0.35
Axin 13/49 (26.5%) 26/49 (73.5%) 34/61 (55.7%) 27/61 (44.3%) 0.04

























Fig. 2 – Photomicrograph of colorectal carcinoma with
positive immunoreactivity antibody axin in the cytoplasm
of tumor cells (immunohistochemistry; 100×).NNCRT, non-neoplastic colorectal tissue; CRC, colorectal carcinoma; 
etastases in the liver and/or other locations were observed
n 14 cases (21.9%). Relapse occurred in 13 patients (20.3%),
nd 12 patients (18.7%) died. The average follow-up time was
9.1 months (range, 3–36 months).
Immunoexpression of the Wnt-1 protein in non-neoplastic
olorectal tissue and colorectal carcinoma showed no sig-
iﬁcant difference (p = 1.0). Immunoexpression of the Wnt-2
rotein in colorectal carcinoma was signiﬁcantly lower
p = 0.05) than in non-neoplastic colorectal tissue (Table 1 and
ig. 1). Immunoexpression of the Wnt-5a protein in non-
eoplastic colorectal tissue and colorectal carcinoma showed
o signiﬁcant difference (p = 0.28) between them. Immuno-
xpression of the Frizzled-1 and Frizzled-5 proteins showed
o signiﬁcant differences (p = 0.7 and p = 0.35, respectively).
xin protein immunoexpression was signiﬁcantly reduced
p = 0.039) in non- neoplastic colorectal tissue relative to neo-
lastic tissue (Table 1 and Fig. 2).
iscussion
espite the evidence on Wnt  proteins and their Frizzled recep-
ors and their participation in colorectal carcinogenesis, the
nteractions and regulatory mechanisms of these proteins are
ot completely understood.22 Several mutations in oncogenes,
ig. 1 – Photomicrograph of colorectal carcinoma with
ositive immunoreactivity for Wnt-2 antibody in the
ytoplasm of tumor cells (immunohistochemistry; 200×).tumor suppressor genes and other proteins that comprise
the signal transduction pathways have been associated with
colorectal neoplasias. However, few of these mutations, when
known, occur in all tumors and at all stages of the disease.
Although Wnt-1 is one of the most studied proteins of
the canonical Wnt  signaling pathway, there are few studies
showing the expression of this protein in colorectal tissues.
Stanczak et al.23 showed increased expression of Wnt-1 pro-
tein in normal colorectal mucosa and decreased expression of
this protein in tumor tissue. Holcombe et al.11 found abundant
expression of Wnt-1 protein in normal mucosa and colorectal
tumor tissue. In the present study, no signiﬁcant difference
was found when the expression of Wnt-1 in non-neoplastic
colorectal tissue was compared with colorectal tumor tissue.
These conﬂicting results could suggest that other mechanisms
may be involved in colorectal carcinogenesis in addition to the
activation of Wnt-1 protein.
Wnt-2 protein is an important inducer of the Wnt  canonical
signaling pathway.22 Other authors11,12 have shown little or
even the absence of expression in normal colorectal mucosa
but increased immunoexpression in colorectal tumor tissue.
The current study showed strong expression of Wnt-2 protein
in non-neoplastic colorectal tissue and reduced expression in
tumor tissue.
j). 2 0
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Of the proteins involved in the non-canonical Wnt
signaling pathway, Wnt-5a protein appears to have tumor-
suppressor behavior primarily for its ability to inhibit the
canonical Wnt  signaling pathway and reduce the pool of -
catenin protein in the cytoplasm.10 Dejmek et al.24 showed
that expression of Wnt-5a is associated with an increased ﬁve-
year survival in patients with Dukes’ stage B CRC. Previous
studies11,22 using RT-PCR found Wnt-5a protein expression in
normal cell lines, particularly at the base of the crypts, but
not in CRC tissues. The present sampling, however, found
markedly reduced expression of Wnt-5a protein in both neo-
plastic and non-neoplastic colorectal tissues. This fact can be
explained by the use of non-neoplastic tissues from the same
patients as controls because it has been demonstrated that
loss of Wnt-5a gene stimulates the canonical Wnt  signaling
pathway in patients with CRC.25 Dejmek et al.24 suggested that
expression of Wnt-5a protein in patients with CRC seems to be
associated with the early stages of neoplasia, a result different
from the ﬁndings of the present study in which the majority
of patients were in the more  advanced stages of CRC.
The interaction of Wnt  proteins with Frizzled receptors is
considered crucial to the understanding of Wnt  signaling, both
in embryogenesis and in development of tumors.19 Despite
intensive research into the Wnt  signaling pathway and the
participation of its constitutive proteins,26 the role of the Friz-
zled proteins in this condition remains unclear. Few studies
have examined the expression of Frizzled receptors in colo-
rectal tissue. You et al.27 observed that the Frizzled-1 and
Frizzled-2 receptors were overexpressed in dysplastic mucosa
adjacent to CRC, underexpressed in normal mucosa and not
expressed in neoplastic tissue. In patients with sporadic CRC,
Holcombe et al.11 found expression of Frizzled-1 and Frizzled-
2 receptors only in patients with poorly differentiated lesions,
suggesting that the regulation of the Frizzled proteins is an
important step in the process of tumor invasion. In the present
study, both the Frizzled-1 and Frizzled-5 receptors showed
decreased expression in non-neoplastic colorectal tissue and
CRC.
The axin gene acts as a tumor suppressor gene through a
negative feedback system, regulating the signal responses of
the Wnt  signaling pathway.28 Normally, axin protein reduces
the levels of -catenin in the cytoplasm. However, mutations
in this gene lead to an increase in the concentration of -
catenin in colorectal tumors. Jin et al.29 analyzed 54 CRC
specimens from patients and found that 11% had axin gene
mutations, suggesting that this change may be associated
with colorectal carcinogenesis. Webster et al.30 studied the
axin gene in 4 different CRC cell lines and showed that muta-
tion of this gene alters its binding capacity to the GSK3 gene
thereby preventing the formation of the destructor protein
complex of -catenin.
Thus, abnormally high levels of axin protein expression can
mask a functional difference because the levels of expression
of this gene tend to be low.5 Such an effect may explain the
fact that strong expression of this protein in tumor tissue was
found in this study, while reduced expression was found in
non-neoplastic colorectal tissue, a ﬁnding also observed by
Hughes and Brady.28
Some of the differences found in the results of the cur-
rent study, when compared with those found in the literature, 1 5;3  5(3):156–161
can be explained by factors related to the method used in the
research. Most studies15,16,27 used an RT-PCR method, whereas
the current study used an immunohistochemical method.
Another important factor was the use of tissue culture cell
lines for analysis in these studies. Other authors12,26 showed
differences in the expression of proteins in neoplastic tis-
sues of patients compared with the same tumor cell line from
tissue culture. More sophisticated methods such as in situ
hybridization or laser capture microdissection (LCM) could
better elucidate these issues.
Thus, in the present study, different degrees of expres-
sion of Wnt, Frizzled receptors and axin proteins were
found in neoplastic colorectal tissues compared with non-
neoplastic tissues, ﬁndings that were also observed by other
authors.11,12,23,26 Because the Wnt  signaling pathway and APC
gene11 pathway act in the transformation of normal epithe-
lium into proliferative epithelium, it is possible that most of
the proteins of these pathways involved in tumorigenesis are
expressed both in the tumor tissue and in the adjacent mucosa
of these same tumors.
The results showing the absence of increased expression of
proteins of the non-canonical Wnt  pathway (Wnt-1, Wnt-5a,
Frizzled-1 and Frizzled-5) suggest that this route is not fully
enabled in sporadic CRC, and therefore contributes less to the
genesis of CRC. However, the Wnt-2 protein, typical of the
canonical Wnt  signaling pathway, showed a signiﬁcant differ-
ence between the levels of immunohistochemical expression
in non-neoplastic colorectal tissue and tumor tissue. The
higher expression of Wnt-2 protein in non- neoplastic colo-
rectal tissue suggests the participation of the proto-oncogene
Wnt-2 during the early and/or hyperproliferative stage of pre-
neoplastic changes of the colorectal mucosa.
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